<DOC>
	<DOCNO>NCT00911612</DOCNO>
	<brief_summary>Our hypothesis medication approve treatment high blood cholesterol level , Colesevelam HCl ( WELCHOL ) , decrease colonic transit permeability patient diarrhea due irritable bowel syndrome . This effect think result effect medication bile acid , cause diarrhea .</brief_summary>
	<brief_title>Does Welchol ( Colesevelam Hydrochloride ) Improve Colonic Transit Diarrhea-predominant Irritable Bowel Syndrome ( D-IBS ) ?</brief_title>
	<detailed_description>Background : Irritable bowel syndrome ( IBS ) affect 15 % U.S. population , 5 % predominant diarrhea ; current treatment suboptimal may tolerate , lead side effect insufficient benefit . Bile acid malabsorption ( BAM ) recognize cause chronic diarrhea investigate mechanism phenotype diarrhea predominant IBS ( D-IBS ) . Increased exposure colon bile acid may result accelerate small bowel transit abnormal function apical sodium bile acid transporter ( ASBT ) postulate cause functional diarrhea symptom D-IBS number mechanism , increase colonic secretion , mucosal permeability . Recent preliminary data suggest dos chenodeoxycholate ( CDC ) approve dissolution gall stone associate accelerated colonic empty looser stool consistency . Hypothesis : The bile acid bind agent , Colesevelam HCl , decrease colonic transit permeability patient D-IBS . Specific Aim : To investigate effect Colesevelam , bind bile acid small intestine reduces concentration bile acid colon , colonic transit , permeability bowel function patient D-IBS . Methods : Twenty-four D-IBS participant randomize placebo treatment Welchol ( Colesevelam HCL ) 1.875 gram b.i.d . 12-14 day . A baseline colon transit , 24 hour urine colon permeability , blood serum 7 alpha-hydroxy-4-cholesten-3-one ( 7 alpha-HCO ) measure venous blood DNA collect store . The measurement serum 7 alpha-hydroxy-4-cholesten-3-one ( 7 alpha-HCO ) , measurement hepatic cholesterol synthesis , closely related fecal loss bile acid , validate method screen BAM . Following treatment 12 day , transit permeability study repeat . Bowel function symptom record duration study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Colesevelam Hydrochloride</mesh_term>
	<criteria>Patients DIBS Aged 1865 year No abdominal surgery ( except appendectomy cholecystectomy long patient IBSdiarrhea symptom precede cholecystectomy Participants know chronic liver disease Aspartate aminotransferase ( AST ) Alanine transaminase ( ALT ) &gt; 2.0 X upper limit normal Hypertriglyceridemia pancreatitis history Diabetes hypoglycemia Significant coagulation disorder History bowel obstruction Serum triglycerides &gt; 500 mg/dL History vitamin A , D , E , K deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>bile acid</keyword>
	<keyword>malabsorption</keyword>
	<keyword>permeability</keyword>
	<keyword>diarrhea</keyword>
	<keyword>IBS</keyword>
	<keyword>stool</keyword>
</DOC>